These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31391887)

  • 21. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery.
    Pérot S; Sperandio O; Miteva MA; Camproux AC; Villoutreix BO
    Drug Discov Today; 2010 Aug; 15(15-16):656-67. PubMed ID: 20685398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding site detection and druggability prediction of protein targets for structure-based drug design.
    Yuan Y; Pei J; Lai L
    Curr Pharm Des; 2013; 19(12):2326-33. PubMed ID: 23082974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural insights into the molecular basis of the ligand promiscuity.
    Sturm N; Desaphy J; Quinn RJ; Rognan D; Kellenberger E
    J Chem Inf Model; 2012 Sep; 52(9):2410-21. PubMed ID: 22920885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying and characterizing binding sites and assessing druggability.
    Halgren TA
    J Chem Inf Model; 2009 Feb; 49(2):377-89. PubMed ID: 19434839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform.
    Chopra G; Samudrala R
    Curr Pharm Des; 2016; 22(21):3109-23. PubMed ID: 27013226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analyzing Promiscuity at the Level of Active Compounds and Targets.
    Bajorath J
    Mol Inform; 2016 Dec; 35(11-12):583-587. PubMed ID: 27870240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding sites in membrane proteins--diversity, druggability and prospects.
    Adams R; Worth CL; Guenther S; Dunkel M; Lehmann R; Preissner R
    Eur J Cell Biol; 2012 Apr; 91(4):326-39. PubMed ID: 21872966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target.
    Adeniji EA; Olotu FA; Soliman MES
    Anticancer Agents Med Chem; 2018; 18(11):1540-1550. PubMed ID: 30019652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simple and fuzzy method to align and compare druggable ligand-binding sites.
    Schalon C; Surgand JS; Kellenberger E; Rognan D
    Proteins; 2008 Jun; 71(4):1755-78. PubMed ID: 18175308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding site comparisons for target-centered drug discovery.
    Konc J
    Expert Opin Drug Discov; 2019 May; 14(5):445-454. PubMed ID: 30856011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similarity networks of protein binding sites.
    Zhang Z; Grigorov MG
    Proteins; 2006 Feb; 62(2):470-8. PubMed ID: 16299776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins.
    Hussein HA; Borrel A; Geneix C; Petitjean M; Regad L; Camproux AC
    Nucleic Acids Res; 2015 Jul; 43(W1):W436-42. PubMed ID: 25956651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
    Fauman EB; Rai BK; Huang ES
    Curr Opin Chem Biol; 2011 Aug; 15(4):463-8. PubMed ID: 21704549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity.
    Park K; Lee S; Ahn HS; Kim D
    Mol Biosyst; 2009 Aug; 5(8):844-53. PubMed ID: 19603120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PocketPicker: analysis of ligand binding-sites with shape descriptors.
    Weisel M; Proschak E; Schneider G
    Chem Cent J; 2007 Mar; 1():7. PubMed ID: 17880740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots.
    Gilberg E; Gütschow M; Bajorath J
    ACS Omega; 2019 Jan; 4(1):1729-1737. PubMed ID: 31459430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying Promiscuous Compounds with Activity against Different Target Classes.
    Feldmann C; Miljković F; Yonchev D; Bajorath J
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31752252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving ligand 3D shape similarity-based pose prediction with a continuum solvent model.
    Kumar A; Zhang KYJ
    J Comput Aided Mol Des; 2019 Dec; 33(12):1045-1055. PubMed ID: 31463704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.